Needham raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $30 from $27 and keeps a Buy rating on the shares.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- ACADIA Pharmaceuticals: Buy Rating Affirmed Amid Legal Victory and Promising R&D Prospects
- District court finds Aurobindo infringes Acadia Pharmaceuticals patent claims
- Acadia Pharmaceuticals files to sell 43.58M shares of common stock for holders
- ACADIA Pharmaceuticals Reports Strong Q1 Earnings Growth
- Positive Outlook for ACADIA Pharmaceuticals: Buy Rating Affirmed Amid Strategic Growth Initiatives and Promising Pipeline Developments